The gut microbiome as novel cardio-metabolic target: the time has come!
Recent studies reveal a potential contribution of intestinal microbes in the expression of certain human cardio-metabolic diseases. The mechanisms through which intestinal microbiota and/or their metabolic products alter systemic homoeostasis and cardio-metabolic disease risks are just beginning to be dissected. Intervention studies in humans aiming to either selectively alter the composition of the intestinal microbiota or to pharmacologically manipulate the microbiota to influence production of their metabolites are crucial next steps. The intestinal microbiome represents a new potential therapeutic target for the treatment of cardio-metabolic diseases.
Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, AMC-UvA, Meibergdreef 9, room F4-159.2, 1105 AZ Amsterdam, The Netherlands.
Sarah
S
Vinjé
Erik
E
Stroes
Max
M
Nieuwdorp
Stan L
SL
Hazen
D050197:Atherosclerosis / Q000378:metabolism / Q000382:microbiology; D003924:Diabetes Mellitus, Type 2 / Q000378:metabolism / Q000382:microbiology; D005243:Feces / Q000382:microbiology; D005759:Gastroenteritis / Q000378:metabolism / Q000382:microbiology; D041981:Gastrointestinal Tract / Q000378:metabolism / Q000382:microbiology*; D006801:Humans; D050356:Lipid Metabolism / Q000502:physiology; D064307:Microbiota; D009765:Obesity / Q000378:metabolism / Q000382:microbiology / Q000628:therapy; D018570:Risk Assessment / Q000379:methods / Q000639:trends; D013927:Thrombosis / Q000378:metabolism / Q000382:microbiology
Atherothrombosis; Gutmicrobiota; Insulin resistance; Obesity; TMAO; Therapy; Vascular inflammation